Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accounts Payable and Accrued Expenses

9 Months Ended

Sep. 30, 2023

Note 8 - Accounts Payable and Accrued Expenses

At September 30, 2023 and December 31, 2022, accounts payable and accrued expenses consisted of the following ($ in thousands):


	September 30,		December 31,
	2023		2022
Accounts payable	$	7,957	$	11,535
Accrued compensation		1,016		1,195
Accrued Research and development		7,060		7,289
Other		357		278
Total accounts payable and accrued expenses	$	16,390	$	20,297